Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2

Caroline Diorio, Sarah E. Henrickson, Laura A. Vella, Kevin O. McNerney, Julie Chase, Chakkapong Burudpakdee, Jessica H. Lee, Cristina Jasen, Fran Balamuth, David M. Barrett, Brenda L. Banwell, Kathrin M. Bernt, Allison M. Blatz, Kathleen Chiotos, Brian T. Fisher, Julie C. Fitzgerald, Jeffrey S. Gerber, Kandace Gollomp, Christopher Gray, Stephan A. GruppRebecca M. Harris, Todd J. Kilbaugh, Audrey R. Odom John, Michele Lambert, Emily J. Liebling, Michele E. Paessler, Whitney Petrosa, Charles Phillips, Anne F. Reilly, Neil D. Romberg, Alix Seif, Deborah A. Sesok-Pizzini, Kathleen E. Sullivan, Julie Vardaro, Edward M. Behrens, David T. Teachey, Hamid Bassiri

Research output: Contribution to journalArticlepeer-review

275 Scopus citations

Abstract

BACKGROUND. Initial reports from the severe acute respiratory coronavirus 2 (SARS–CoV-2) pandemic described children as being less susceptible to coronavirus disease 2019 (COVID-19) than adults. Subsequently, a severe and novel pediatric disorder termed multisystem inflammatory syndrome in children (MIS-C) emerged. We report on unique hematologic and immunologic parameters that distinguish between COVID-19 and MIS-C and provide insight into pathophysiology. METHODS. We prospectively enrolled hospitalized patients with evidence of SARS–CoV-2 infection and classified them as having MIS-C or COVID-19. Patients with COVID-19 were classified as having either minimal or severe disease. Cytokine profiles, viral cycle thresholds (Cts), blood smears, and soluble C5b-9 values were analyzed with clinical data. RESULTS. Twenty patients were enrolled (9 severe COVID-19, 5 minimal COVID-19, and 6 MIS-C). Five cytokines (IFN-γ, IL-10, IL-6, IL-8, and TNF-α) contributed to the analysis. TNF-α and IL-10 discriminated between patients with MIS-C and severe COVID-19. The presence of burr cells on blood smears, as well as Cts, differentiated between patients with severe COVID-19 and those with MIS-C. CONCLUSION. Pediatric patients with SARS–CoV-2 are at risk for critical illness with severe COVID-19 and MIS-C. Cytokine profiling and examination of peripheral blood smears may distinguish between patients with MIS-C and those with severe COVID-19. FUNDING. Financial support for this project was provided by CHOP Frontiers Program Immune Dysregulation Team; National Institute of Allergy and Infectious Diseases; National Cancer Institute; the Leukemia and Lymphoma Society; Cookies for Kids Cancer; Alex’s Lemonade Stand Foundation for Childhood Cancer; Children’s Oncology Group; Stand UP 2 Cancer; Team Connor; the Kate Amato Foundations; Burroughs Wellcome Fund CAMS; the Clinical Immunology Society; the American Academy of Allergy, Asthma, and Immunology; and the Institute for Translational Medicine and Therapeutics.

Original languageEnglish
Pages (from-to)5967-5975
Number of pages9
JournalJournal of Clinical Investigation
Volume130
Issue number11
DOIs
StatePublished - 2 Nov 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2'. Together they form a unique fingerprint.

Cite this